Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective

Biomed Pharmacother. 2022 Feb:146:112558. doi: 10.1016/j.biopha.2021.112558. Epub 2021 Dec 22.

Abstract

Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy.

Keywords: Cancer; Immune checkpoints; Immunotherapy; ScRNA-seq.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antineoplastic Agents, Immunological / pharmacology*
  • Cancer Vaccines / pharmacology
  • Cytokines / pharmacology
  • Humans
  • Immune Checkpoint Inhibitors / pharmacology
  • Immunotherapy, Adoptive / methods
  • Neoplasms / pathology*
  • Precision Medicine / methods*
  • Sequence Analysis, RNA / methods
  • Signal Transduction / physiology

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Cancer Vaccines
  • Cytokines
  • Immune Checkpoint Inhibitors